Study short name: MIS BAIR (Melbourne Infant Study: BCG for Allergy & Infection Reduction)
Study full name: A randomised, controlled trial to determine if BCG immunisation at birth prevents the development of allergy & infection in infants
Principle Investigator: Nigel Curtis
Administering Institute: Murdoch Children’s Research Institute
Major funding sources: National Health and Medical Research Council (NHMRC), Royal Children’s Hospital Foundation, University of Melbourne and Murdoch Children’s Research Institute
Study focus: Prevention
Study design: Intervention
Main study aim: To assess whether the BCG vaccine will prevent food allergy, eczema and lower respiratory tract infections in the first 5 years of life.
Additional study information: Study participants randomised to group 1 received a single 0.05 mL intradermal injection of BCG Vaccine SSI or BCG 10 Vaccine over the distal insertion of the deltoid muscle onto the humerus approximately one third down the upper left arm.
Study population: 1272 healthy newborns randomised in the first 10 days of life.
Study status: Recruitment completed September 2016. Data collection ongoing, through February 2022.
Where can I find more information?
Last modified: April 9th 2019 | Date created: April 9th 2019